Heini Lassus - Gynecology

Author Information

H. Lassus is affiliated with the Department of Obstetrics and Gynecology, Gynecologic Oncology at the University of Helsinki and Helsinki University Hospital, located at Haartmaninkatu 2, PO Box 140, 00029 HUS Helsinki, Finland. This information was sourced from PubMed.

Research Contributions

H. Lassus has made significant contributions to the field of gynecologic oncology, with a particular focus on ovarian cancer and its associated molecular and clinical characteristics. Notable research includes the molecular classification of endometriosis-associated ovarian carcinomas and the study of clinical factors and biomarker profiles in endometrioid ovarian carcinoma. Additionally, Lassus has explored the impact of the tumor microenvironment on immunotherapy outcomes and investigated the role of glucocorticoids in chemoresistance in ovarian cancer.

Aliases

The author is known by several aliases, including H Lassus and Heini Lassus. Based on the available information, Heini Lassus appears to be the most appropriate full name.

Publication and Citation Metrics

Metric	Value
Total Citation Count	3168
H-index	27
Total Number of Papers	60

Publications:

TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.

DOI: 10.1016/j.ygyno.2022.03.016

Year: 2022

Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype.

DOI: 10.1158/1535-7163.MCT-21-0622

Year: 2022

Incidence of extraovarian clear cell cancers in women with surgically diagnosed endometriosis: A cohort study

DOI: 10.1371/journal.pone.0253270

Year: 2021

Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype

DOI: 10.1101/2021.03.31.437804

Year: 2021

Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade.

DOI: 10.1016/j.ygyno.2021.10.078

Year: 2021

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity

DOI: 10.1136/jitc-2019-000188

Year: 2020

Abstract A15: Rewiring the tumor microenvironment with an oncolytic virus to enhance and support tumor-infiltrating lymphocytes for ovarian cancer immunotherapy

DOI: 10.1158/2326-6074.TUMIMM18-A15

Year: 2020

405 Real-life response to standard of care in advanced ovarian cancer – an observational multi-national cohort study (RESPONSE)

DOI: 10.1136/ijgc-2020-esgo.131

Year: 2020

Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness

DOI: 10.1038/s41419-020-03009-4

Year: 2020

Revamping the ovarian tumour microenvironment with an oncolytic adenovirus yields enhanced tumour-infiltrating lymphocyte anti-tumour activity

DOI: 10.1093/annonc/mdz452.020

Year: 2019

How to Stay Updated with Coding Changes?

How Do Environmental Toxins Affect Women's Health?

How is Diffusion Capacity Measured?

Is the Rubella Vaccine Safe During Pregnancy?

How Can Gynecologists Support Overwhelmed Patients?

Can respiratory medications be used during pregnancy?

What are some notable studies published in BJOG?

Why is Infection Control Important in Gynecology?

What are Some Commonly Used PRO Instruments in Gynecology?

What Should You Do Before a Cervical Swab?

Partnered Content Networks

Relevant Topics